Evasion of Antigen Presentation by Rhesus CMV

恒河猴 CMV 逃避抗原呈递

基本信息

  • 批准号:
    6968891
  • 负责人:
  • 金额:
    $ 32.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic infections and re-infections by human cytomegalovirus (HCMV) cannot be eliminated by the host's immune system despite an extraordinary strong T cell response. Viral stealth strategies preventing the activation of immune cells and the recognition of virally infected cells are thought to be essential to escape immune eradication. Inhibiting the presentation of viral antigens by major histocompatibility complex (MHC) molecules is thought to play a key role in cytomegaloviral immune escape. However, the role of inhibiting MHC presentation for HCMV pathogenesis and persistence has not been established since infections by cytomegaloviruses are highly host-restricted and HCMV does not infect immunocompetent animals. Besides chimpanzee CMV, which is not a feasible animal model, the closest relative of HCMV is Rhesus CMV (RhCMV) which infects non-human primates. Similar to HCMV, we observed that RhCMV is capable of re-infecting seropositive animals and establishing a persistent infection. Using this new model, we will test the hypothesis that preventing expression of MHC I is essential for the establishment and maintenance of persistent infection in immunocompetent hosts. We show that RhCMV encodes inhibitors of MHC assembly that are functional and sequence homologues of the HCMV US6-family of glycoproteins US2, US3, US6 and US11. We further demonstrate RhCMV encodes additional modulator(s) of MHC I expression within a 3kb genomic fragment, Rh175-180 that encodes RhCMV-specific genes but also overlaps with the transcript of Rh181, the RhCMV homologue of HCMV US1. This novel mechanism, termed viral interference with heavy chain expression (VIHCE), acts post-transcriptionally but prior to completion of heavy chain synthesis. Thus, VIHCE precedes inhibition of MHC I assembly and transport by US6-related proteins. The goals of this proposal are i) to identify which of the gene products encoded in the Rh175-181 region are responsible for VIHCE, ii) to characterize the molecular mechanism of VIHCE, and iii) to determine the role of preventing MHC I expression, assembly or transport for escaping immune detection by CD8+ lymphocytes during establishment and maintenance of persistent infection of immunocompetent animals.
描述(由申请人提供):人类巨细胞病毒(HCMV)的慢性感染和再感染不能被宿主的免疫系统消除,尽管有非常强的T细胞反应。防止免疫细胞激活和识别病毒感染细胞的病毒隐身策略被认为是逃避免疫根除的必要条件。通过主要组织相容性复合体(MHC)分子抑制病毒抗原的呈递被认为在巨细胞病毒免疫逃逸中起关键作用。然而,抑制MHC呈递在HCMV发病机制和持久性中的作用尚未确定,因为巨细胞病毒感染是高度受宿主限制的,而且HCMV不会感染免疫能力强的动物。除了黑猩猩巨细胞病毒不是可行的动物模型外,HCMV最近的亲戚是感染非人类灵长类动物的恒河猴巨细胞病毒(RhCMV)。与HCMV类似,我们观察到RhCMV能够再次感染血清阳性动物并建立持续感染。利用这个新模型,我们将验证一个假设,即阻止MHC I的表达对于在免疫功能正常的宿主中建立和维持持续感染是必不可少的。我们发现,RhCMV编码MHC组装抑制剂,这些抑制剂是HCMV US6家族糖蛋白US2、US3、US6和US11的功能和序列同源物。我们进一步证明了RhCMV在一个3kb的基因组片段Rh175-180中编码MHC I表达的额外调节剂,该片段编码RhCMV特异性基因,但也与RhCMV US1的RhCMV同源物Rh181的转录物重叠。这种新机制被称为病毒干扰重链表达(VIHCE),在转录后但在重链合成完成之前起作用。因此,VIHCE先于us6相关蛋白对MHC I组装和运输的抑制。本研究的目的是:1)确定在Rh175-181区编码的哪些基因产物与VIHCE有关;2)表征VIHCE的分子机制;3)确定在免疫功能正常动物的持续感染建立和维持过程中,阻止MHC i的表达、组装或运输以逃避CD8+淋巴细胞的免疫检测的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Klaus J Fruh其他文献

Klaus J Fruh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Klaus J Fruh', 18)}}的其他基金

Non-canonical epitope presentation and antigen processing by MHC-E
MHC-E 的非典型表位呈递和抗原加工
  • 批准号:
    10801509
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9982274
  • 财政年份:
    2017
  • 资助金额:
    $ 32.66万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9238234
  • 财政年份:
    2017
  • 资助金额:
    $ 32.66万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9751633
  • 财政年份:
    2017
  • 资助金额:
    $ 32.66万
  • 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
  • 批准号:
    8607501
  • 财政年份:
    2013
  • 资助金额:
    $ 32.66万
  • 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
  • 批准号:
    8423271
  • 财政年份:
    2013
  • 资助金额:
    $ 32.66万
  • 项目类别:
MECHANISMS OF IMMUNE VULNERABILITY OF THE ELDERLY TO THE WEST NILE VIRUS
老年人对西尼罗河病毒免疫脆弱的机制
  • 批准号:
    8357751
  • 财政年份:
    2011
  • 资助金额:
    $ 32.66万
  • 项目类别:
EVASION OF ANTIGEN PRESENTATION BY RHESUS CYTOMEGALOVIRUS
恒河猴巨细胞病毒逃避抗原呈递
  • 批准号:
    8357750
  • 财政年份:
    2011
  • 资助金额:
    $ 32.66万
  • 项目类别:
MODULATION OF INNATE IMMUNE RESPONSES BY CYTOMEGALOVIRUS
巨细胞病毒对先天免疫反应的调节
  • 批准号:
    8357775
  • 财政年份:
    2011
  • 资助金额:
    $ 32.66万
  • 项目类别:
Development and Analysis of Replication-Deficient CMV Vectors
复制缺陷型 CMV 载体的开发和分析
  • 批准号:
    8117930
  • 财政年份:
    2011
  • 资助金额:
    $ 32.66万
  • 项目类别:

相似海外基金

Role of novel RNA binding protein LARP6 in alcoholic cardiomyopathy
新型RNA结合蛋白LARP6在酒精性心肌病中的作用
  • 批准号:
    10593688
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Targeting of RNA-binding protein FXR1 in HNSCC
HNSCC 中 RNA 结合蛋白 FXR1 的靶向
  • 批准号:
    10571379
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Mechanisms driving Autosomal Dominant Polycystic Kidney Disease: The novel role of the RNA-binding protein ANKHD1.
常染色体显性多囊肾病的驱动机制:RNA 结合蛋白 ANKHD1 的新作用。
  • 批准号:
    MR/T04201X/2
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
    Fellowship
Identify the role of RNA-binding protein in activating anti-tumor immunity by directly decaying PD-L1-3'UTR
通过直接降解 PD-L1-3UTR 鉴定 RNA 结合蛋白在激活抗肿瘤免疫中的作用
  • 批准号:
    23KJ1296
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Anti-inflammatory Signaling of RNA-binding Protein, Tristetraprolin, During Myocardial Infarction
RNA 结合蛋白 Tristetraprolin 在心肌梗死期间的抗炎信号传导
  • 批准号:
    10644962
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy
tau蛋白病中含有RNA结合蛋白SFPQ的病理应激颗粒的形成和功能
  • 批准号:
    10581946
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
ERK-mediated regulation of RNA binding protein condensation during female germ cell development
ERK 介导的雌性生殖细胞发育过程中 RNA 结合蛋白凝聚的调节
  • 批准号:
    10514951
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
  • 批准号:
    10634764
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
Post-transcriptional regulation by the YBX3 RNA-binding protein in skeletal muscle
骨骼肌中 YBX3 RNA 结合蛋白的转录后调节
  • 批准号:
    10439013
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
Evolution of RNA Binding Protein Regulation of Brain Development
RNA结合蛋白对大脑发育调节的进化
  • 批准号:
    2735241
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了